Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer

Clinical Trial ID NCT00849121

PubWeight™ 12.79^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00849121

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trial watch: DNA vaccines for cancer therapy.	Oncoimmunology	2013	1.11
2	Current status of immunological therapies for prostate cancer.	Curr Opin Urol	2010	1.06
3	Prostate cancer vaccines: Update on clinical development.	Oncoimmunology	2013	0.98
4	Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.	Curr Opin Oncol	2012	0.92
5	Update on prostate cancer vaccines.	Cancer J	2011	0.88
6	Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.	Clin Cancer Res	2014	0.88
7	Preclinical and clinical development of DNA vaccines for prostate cancer.	Urol Oncol	2013	0.86
8	Trial watch: Naked and vectored DNA-based anticancer vaccines.	Oncoimmunology	2015	0.83
9	Current status of immunological approaches for the treatment of prostate cancer.	Curr Opin Urol	2012	0.81
10	Beyond sipuleucel-T: immune approaches to treating prostate cancer.	Curr Treat Options Oncol	2014	0.79
11	DNA vaccination for prostate cancer: key concepts and considerations.	Cancer Nanotechnol	2015	0.78
12	Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.	J Clin Immunol	2011	0.78
13	DNA Vaccines for Prostate Cancer.	Curr Cancer Ther Rev	2012	0.77
14	Immunotherapy for prostate cancer enters its golden age.	Clin Med Insights Oncol	2012	0.77
15	Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.	J Immunother Cancer	2013	0.75